Shyama Sidique
Sanford-Burnham Institute for Medical Research
7 Papers
126 Citations
Shyama Sidique is an academic researcher from Sanford-Burnham Institute for Medical Research. The author has contributed to research in topics: Allosteric regulation & Metabotropic glutamate receptor. The author has an hindex of 6, co-authored 7 publications. Previous affiliations of Shyama Sidique include Conrad Hotels & Torrey Pines Institute for Molecular Studies.
Chat about Author
Papers
Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP).
Shyama Sidique,Robert Ardecky,Ying Su,Sonoko Narisawa,Brock Brown,José Luis Millán,Eduard Sergienko,Nicholas D. P. Cosford +7 more
TL;DR: The design, synthesis and in vitro evaluation of a series of pyrazole derivatives of a screening hit which are potent TNAP inhibitors exhibiting IC(50) values as low as 5nM are reported.
85
Structure–activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase
Shyama Sidique,Sergey A. Shiryaev,Boris I. Ratnikov,Ananda Herath,Ananda Herath,Ying Su,Ying Su,Alex Y. Strongin,Nicholas D. P. Cosford,Nicholas D. P. Cosford +9 more
TL;DR: The design, synthesis and in vitro evaluation of pyrazole derivatives that are inhibitors of WNV NS2B-NS3 proteinase with greatly improved stability in the assay medium are reported.
72
Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure–Activity Relationships and Assessment in a Rat Model of Nicotine Dependence
Shyama Sidique,Raveendra-Panickar Dhanya,Douglas J. Sheffler,Hilary Highfield Nickols,Li Yang,Russell Dahl,Arianna Mangravita-Novo,Layton H. Smith,Manoranjan S. D’Souza,Svetlana Semenova,P. Jeffrey Conn,Athina Markou,Nicholas D. P. Cosford +12 more
TL;DR: The data, showing for the first time efficacy of an mGlu(2) receptor PAM in this in vivo model, suggest potential utility for the treatment of nicotine dependence in humans.
Patent
Positive allosteric modulators of group ii mglurs
Nicholas D. P. Cosford,Dhanya Raveendra Panickar,Shyama Sidique +2 more
- 18 Mar 2011
TL;DR: In this paper, the melabotropic glutamatc subtype 2 (mGlu2) receptor was used as a positive ailosteric modulator for treating CNS disorders associated with the mGlu 2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.
20
Patent
Modulateurs allostériques positifs de mglurs de type 2
Nicholas Cosford,Dhanya Raveendra Panickar,Shyama Sidique +2 more
- 18 Mar 2011
TL;DR: The presente invention concerne des composes et compositions, and des procedes d'utilisation de ces composes and compositions, en tant que modulateurs allosteriques positifs du recepteur metabotropique du glutamate de type 2 (mGlu2), and pour le traitement de troubles du systeme nerveux central associes au recepteur mGlu 2 comprenant la schizophrenie, l'anxiete, la toxicomanie, par exemple la cocainomanie and le tabagisme